Longitudinal Impact of Smoking and Smoking Cessation on Inflammatory Markers of Cardiovascular Disease Risk
Overview
Affiliations
Objective: To evaluate longitudinal changes in 6 inflammatory markers that predict cardiovascular disease events among smokers making a quit attempt and to characterize their cross-sectional associations between smoking and smoking heaviness.
Approach And Results: In a longitudinal cohort study of contemporary smokers (n=1652), we evaluated (1) independent associations of smoking heaviness markers (exhaled carbon monoxide, cigarettes/d, pack-years) with inflammatory markers (C-reactive protein, D-dimer, fibrinogen, urinary F isoprostane:creatinine [F:Cr] ratio, white blood cell [WBC] count, myeloperoxidase) and (2) the effects of smoking cessation and continued smoking on these inflammatory markers after 1 year, among the 888 smokers who made an aided quit attempt as part of a randomized comparative effectiveness trial or standard care. There were strong, independent associations between smoking heaviness markers and the F:Cr ratio, WBC, and myeloperoxidase (all P<0.001), but not high-sensitivity C-reactive protein, D-dimer, or fibrinogen. Participants were mean (SD) 49.6 years old (11.6), 54% women, 34% non-white, and smoked 16.8 cigarettes/d (8.5) for 27.3 pack-years (18.6). After 1 year, the 344 successful abstainers gained more weight (4.0 [6.0] versus 0.4 [5.7] pounds; P<0.001) and had larger increases in insulin resistance scores (P=0.02) than continuing smokers. Despite these increases, abstainers had significant decreases in F:Cr ratio (P<0.001) and WBC counts (P<0.001). Changes in other markers were not related to quitting.
Conclusions: Smoking heaviness is associated with increased F:Cr ratio, myeloperoxidase, and WBC counts. Cessation improves the F:Cr ratio and WBC counts independent of weight change, suggesting reduced inflammation related to less oxidant stress.
Vascular endothelial cell injury: causes, molecular mechanisms, and treatments.
Xia T, Yu J, Du M, Chen X, Wang C, Li R MedComm (2020). 2025; 6(2):e70057.
PMID: 39931738 PMC: 11809559. DOI: 10.1002/mco2.70057.
An X, Li J, Li Y, Liu H, Bai J, Guo Q Eur Rev Aging Phys Act. 2024; 21(1):26.
PMID: 39358685 PMC: 11448037. DOI: 10.1186/s11556-024-00361-8.
Zang X, Meng X, Liu X, Geng H, Liang J Prev Med Rep. 2023; 36:102441.
PMID: 37781105 PMC: 10534208. DOI: 10.1016/j.pmedr.2023.102441.
Hadate T, Kawamura R, Tabara Y, Maruyama K, Takakado M, Ikeda Y J Hum Genet. 2023; 68(11):745-750.
PMID: 37423942 DOI: 10.1038/s10038-023-01176-8.
The use of biomarkers to guide precision treatment for tobacco use.
Siegel S, Tindle H, Bergen A, Tyndale R, Schnoll R Addict Neurosci. 2023; 6.
PMID: 37089247 PMC: 10121195. DOI: 10.1016/j.addicn.2023.100076.